Product Information

VERAPAMIL ER 180 MG CAPSULE is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $2.8278 per EA under NDC 00378638001. Its NADAC has been published 677 times since Nov 28, 2013.

FDA first approved this application on Apr 20, 1999. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

VERAPAMIL ER 180 MG CAPSULE

verapamil hydrochloride
$2.8278per EA

Strength

180 mg/1

NDC

00378638001

Classification

Generic

Dosage Form

CAPSULE, EXTENDED RELEASE

Route

ORAL

Effective Date

10/21/2026

Active Ingredients

VERAPAMIL HYDROCHLORIDE

Approval Type

Generic (ANDA)

FDA Application

ANDA075138

FDA Approved

4/20/1999

TE Code

AB

On Market Since

5/20/1999

Pharmacological Classes

Calcium Channel Antagonists
Calcium Channel Blocker
Cytochrome P450 3A Inhibitors
Cytochrome P450 3A4 Inhibitors
P-Glycoprotein Inhibitors

Price Statistics

The NADAC for VERAPAMIL ER 180 MG CAPSULE has been published 677 times since Nov 28, 2013, and over the history we have for it it has risen 394.8%. The table below summarizes its recorded NADAC range and movement.

Current price$2.8278 per EA
All-time high$2.8278 (Nov 11, 2026)
All-time low$0.4773 (Feb 18, 2015)
52-week high$2.8278
52-week low$1.0471
Median price$1.1583
Average price$1.1417
Largest weekly change+47.4% (Sep 23, 2026)
Weeks tracked677
Tracking sinceNov 28, 2013

Price History

1W

0.0%

1M

+35.5%

3M

+170.1%

6M

+81.1%

1Y

+79.5%

3Y

+116.6%

5Y

+146.9%

All

+394.8%

Generic Alternatives

The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 63% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of VERAPAMIL ER 180 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for VERAPAMIL ER 180 MG CAPSULE, manufactured by Mylan Pharmaceuticals Inc., is $2.8278 per EA (NDC 00378638001), effective Nov 11, 2026.

How has the price of VERAPAMIL ER 180 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for VERAPAMIL ER 180 MG CAPSULE has risen 394.8%. It has been tracked across 677 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for VERAPAMIL ER 180 MG CAPSULE?

Since Nov 28, 2013, the NADAC for VERAPAMIL ER 180 MG CAPSULE has ranged from a low of $0.4773 (Feb 18, 2015) to a high of $2.8278 (Nov 11, 2026), with a median of $1.1583 per EA.

Are there cheaper alternatives to VERAPAMIL ER 180 MG CAPSULE?

Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, VERAPAMIL SR 180 MG CAPSULE, is $1.0471 per EA — about 63% below VERAPAMIL ER 180 MG CAPSULE.

Who manufactures VERAPAMIL ER 180 MG CAPSULE?

VERAPAMIL ER 180 MG CAPSULE (NDC 00378638001) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.